William Blair analyst Sarah Schram initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating. The company is equipped with a “differentiated” large molecule transport vehicle platform to “reach peak potential,” the analyst tells investors in a research note.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics upgraded to Buy from Hold at Stifel
- Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
- Denali Therapeutics management to meet with B. Riley
- Denali Therapeutics Advances Brain Disease Therapies
- Denali Therapeutics sees Fy24 opex increase of 5%-10% year-over-year